THERAPEUTIC APPLICATIONS OF COW DUNG AND URINE IN MODERN MEDICINE

Abstract

This invention provides a formulation for treating eye infections using cow dung and urine extracts, valued for their antimicrobial and anti-inflammatory properties. With advanced delivery systems such as hydrogels, microneedles, and nano-formulations, the invention presents a safe, natural alternative for ocular infections, bridging traditional knowledge with modern pharmaceutical practices

Specification

Description:FIELD OF THE INVENTION
This invention relates to biotechnology and traditional medicine, focusing on the therapeutic applications of cow dung and urine in treating eye infections. By leveraging their natural antimicrobial properties, the invention explores sustainable and traditional treatment methods, integrating them with modern delivery systems for potential pharmaceutical applications.
BACKGROUND OF THE INVENTION
Eye infections, caused by both gram-positive and gram-negative bacteria, are common and can result in symptoms like redness, itching, inflammation, and visual discomfort. Existing treatments typically involve synthetic antibiotics, which may lead to side effects or resistance with prolonged use. Traditional medicine has long recognized the therapeutic properties of cow dung and urine, valued for their antimicrobial and anti-inflammatory benefits. Cow urine is composed of 95% water, 2.5% urea, and various salts, hormones, and enzymes, containing essential nutrients like iron, calcium, potassium, and sulfur. Despite their proven antimicrobial potential, cow dung and urine are underutilized in modern medical applications due to challenges in collection, sanitation, and public acceptance. This invention aims to address these challenges by developing safe, effective, and culturally sensitive methods to harness cow dung and urine for treating eye infections, offering a natural alternative to conventional pharmaceuticals.
SUMMARY OF THE INVENTION
This summary is provided to introduce a selection of concepts, in a simplified format, that are further described in the detailed description of the invention.
This summary is neither intended to identify key or essential inventive concepts of the invention and nor is it intended for determining the scope of the invention.
To further clarify advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof, which is illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail with the accompanying drawings.
The invention provides a therapeutic formulation incorporating cow dung and urine to treat eye infections. The formulation harnesses the antimicrobial and anti-inflammatory properties of cow dung and urine, with delivery methods that improve bioavailability and effectiveness. Potential delivery methods include hydrogel-based solutions, microneedles, and nano-formulations. By controlling formulation parameters such as pH and viscosity, the invention ensures sustained release and prolonged contact with the ocular surface. This innovation presents a natural, accessible treatment for common eye ailments, promoting traditional medicine in a modern context.
BRIEF DESCRIPTION OF THE DRAWINGS
The illustrated embodiments of the subject matter will be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. The following description is intended only by way of example, and simply illustrates certain selected embodiments of devices, systems, and methods that are consistent with the subject matter as claimed herein, wherein:
FIGURE 1: ILLUSTRATES THE PREPARATION OF COW DUNG AND URINE EXTRACTS, HIGHLIGHTING THE SANITATION AND FILTRATION PROCESSES TO ENSURE PURITY.
FIGURE 2: DEPICTS A HYDROGEL-BASED DELIVERY METHOD FOR THE FORMULATION, DEMONSTRATING SUSTAINED OCULAR RELEASE.
The figures depict embodiments of the present subject matter for the purposes of illustration only. A person skilled in the art will easily recognize from the following description that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the disclosure described herein.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description of various exemplary embodiments of the disclosure is described herein with reference to the accompanying drawings. It should be noted that the embodiments are described herein in such details as to clearly communicate the disclosure. However, the amount of details provided herein is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure as defined by the appended claims.
It is also to be understood that various arrangements may be devised that, although not explicitly described or shown herein, embody the principles of the present disclosure. Moreover, all statements herein reciting principles, aspects, and embodiments of the present disclosure, as well as specific examples, are intended to encompass equivalents thereof.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments. As used herein, the singular forms "a"," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises," "comprising," "includes" and/or "including," when used herein, specify the presence of stated features, integers, steps, operations, elements and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof.
It should also be noted that in some alternative implementations, the functions/acts noted may occur out of the order noted in the figures. For example, two figures shown in succession may, in fact, be executed concurrently or may sometimes be executed in the reverse order, depending upon the functionality/acts involved.
In addition, the descriptions of "first", "second", "third", and the like in the present invention are used for the purpose of description only, and are not to be construed as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Thus, features defining "first" and "second" may include at least one of the features, either explicitly or implicitly.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which example embodiments belong. It will be further understood that terms, e.g., those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
This invention develops a therapeutic formulation based on cow dung and urine extracts, intended to treat bacterial eye infections. The preparation begins with the collection of cow urine and dung under hygienic conditions to prevent contamination. Cow urine undergoes filtration and is boiled to remove ammonia, ensuring the active compounds remain stable and safe for medicinal use. Cow dung is similarly processed to eliminate impurities, then both extracts are analyzed for their antimicrobial and anti-inflammatory properties.
The formulation includes hydrogel-based delivery, wherein the cow dung and urine extracts are incorporated into a pH-sensitive hydrogel for sustained ocular release. Hydrogels are versatile and can be adjusted for viscosity, allowing for enhanced contact time with the eye's surface, thereby maximizing therapeutic efficacy. Additionally, microneedle arrays offer a modern delivery approach, where tiny, dissolvable needles loaded with the cow dung and urine extracts provide painless and targeted delivery to the eye. This method enhances the bioavailability of active compounds, supporting rapid absorption and local therapeutic effects.
The invention further explores nanotechnology, creating nano-formulations with encapsulated bioactive compounds from cow dung and urine. These nano-formulations facilitate deeper penetration into ocular tissues, addressing eye infections more effectively while minimizing systemic side effects. Incorporation into contact lenses or ocular inserts presents another avenue, allowing for continuous, controlled release of bioactive agents.
This invention emphasizes the eco-friendly nature of cow dung and urine as renewable resources with low environmental impact. By establishing a collection and purification process that meets quality control standards, the invention addresses concerns of safety and public perception. The formulation's design aligns with modern medical standards, providing an alternative for eye infection treatment that honors traditional practices while ensuring scientific rigor.
, Claims:1. A therapeutic formulation for treating eye infections, comprising cow dung and urine extracts with antimicrobial and anti-inflammatory properties, designed for ocular application.
2. The formulation as claimed in Claim 1, wherein the cow urine undergoes boiling and filtration to remove contaminants, ensuring its purity for medicinal use.
3. The formulation as claimed in Claim 1, wherein it is delivered through a hydrogel-based delivery system for sustained ocular contact and improved bioavailability.
4. The formulation as claimed in Claim 1, wherein microneedle arrays provide a precise and minimally invasive delivery method for cow dung and urine bioactive compounds to the ocular surface.
5. The formulation as claimed in Claim 1, wherein nano-formulations encapsulate the bioactive compounds, enhancing their penetration and efficacy in ocular tissues.
6. A method for treating bacterial eye infections as claimed in Claim 1, involving the administration of cow dung and urine extract-based formulations using modern delivery techniques.

Documents